Cargando…
STAT3β Enhances Sensitivity to Concurrent Chemoradiotherapy by Inducing Cellular Necroptosis in Esophageal Squamous Cell Carcinoma
SIMPLE SUMMARY: The prognosis of esophageal squamous cell carcinoma (ESCC) patients is poor, with a five-year survival of 15–34%. We examined the expression of STAT3α and STAT3β in pretreatment tumor biopsies of 105 ESCC patients who received concurrent chemoradiotherapy (CCRT) by immunohistochemist...
Autores principales: | Zheng, Zhen-Yuan, Yang, Ping-Lian, Luo, Wei, Yu, Shuai-Xia, Xu, Hong-Yao, Huang, Ying, Li, Rong-Yao, Chen, Yang, Xu, Xiu-E, Liao, Lian-Di, Wang, Shao-Hong, Huang, He-Cheng, Li, En-Min, Xu, Li-Yan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7926856/ https://www.ncbi.nlm.nih.gov/pubmed/33670049 http://dx.doi.org/10.3390/cancers13040901 |
Ejemplares similares
-
Blocking STAT3 signaling augments MEK/ERK inhibitor efficacy in esophageal squamous cell carcinoma
por: Zheng, Zhen-Yuan, et al.
Publicado: (2022) -
Concurrent chemoradiotherapy with raltitrexed and nedaplatin regimen for esophageal squamous cell carcinoma
por: Qiu, Xiangnan, et al.
Publicado: (2020) -
Concurrent chemoradiotherapy with S-1 compared with concurrent chemoradiotherapy with docetaxel and cisplatin for locally advanced esophageal squamous cell carcinoma
por: Zhou, Xi-Lei, et al.
Publicado: (2021) -
A Meta-Analysis of Concurrent Chemoradiotherapy for Advanced Esophageal Cancer
por: Zhu, Li-Li, et al.
Publicado: (2015) -
Comparative study of cisplatin-based definitive concurrent chemoradiotherapy with S-1 versus paclitaxel for unresectable locally advanced esophageal squamous cell carcinoma
por: Fang, Min, et al.
Publicado: (2017)